Last reviewed · How we verify
NCT05176821
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
NA trial testing esomeprazole plus amoxicillin in H. Pylori Infection in 186 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 186 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- esomeprazole plus amoxicillin — full drug profile →
- amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole — full drug profile →
Conditions studied
- H. Pylori Infection — all drugs for H. Pylori Infection →
Sponsor
Shanghai Zhongshan Hospital
Who can join
18 and older, any sex, with H. Pylori Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to evaluate the efficacy and safety of high-dose dual therapy compared with furazolidone-based quadruple therapy as a rescue treatment for helicobacter pylori infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05176821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for H. Pylori Infection
Currently open trials in the same condition.
- NCT07045857 — Recurrence of H Pylori : Incidence and Influential Factors. · NA · recruiting
- NCT07045688 — Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection · NA · recruiting
- NCT07224048 — Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2 · Phase 4 · active not recruiting
- NCT05544396 — Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis. · NA · active not recruiting
- NCT05387005 — Screening Strategy for Gastric Cancer Prevention · NA · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 5 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing